Cellular therapies have transformed the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). which typically does not respond well to salvage chemotherapy. Recently. approximately 40% of r/r DLBCL patients across three different trials achieved a complete remission at 1 year after receiving treatment with autologous chimeric antigen receptor (CAR) T cells (auto-... https://herbsdailyes.shop/product-category/electrolytes-2/